1. Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC. Naohiro Yasuura, Goki Suda, Masatsugu Ohara, Akimitsu Meno, Takuya Sho, Risako Kohya, Takashi Sasaki, Tomoka Yoda, Sonoe Yoshida, Qingjie Fu … Alimentary pharmacology & therapeutics 2024年9月4日
2. Efficacy and Safety of Durvalumab/Tremelimumab in Unresectable Hepatocellular Carcinoma as Immune Checkpoint Inhibitor Rechallenge Following Atezolizumab/Bevacizumab Treatment. Takuya Sho, Goki Suda, Masatsugu Ohara, Risako Kohya, Takashi Sasaki, Sonoe Yoshida, Shunichi Hosoda, Koji Ogawa, Takashi Kitagataya, Osamu Maehara … Targeted oncology 19(5) 769-778 2024年9月
3. Kobayashi N, Suzuki S, Sakamoto Y, Suzuki R, Mori K, Kosugi Y, Saito T, Ma Y, Liang L, Izumi T, Noda K, Okuzaki D, Kanegae Y, Hayashi S, Tanaka Y, Yamashita A, Moriishi K, Matsuura Y, Takeuchi O, Tamura T, Taketomi A, Fukuhara T.NEDD4-binding protein 1 suppresses hepatitis B virus replication by regulating viral RNAs.J Gen Virol.2025.106,(3),10.1099/jgv.0.002082.
4. Shimizu T, Miyoshi M, Kakinuma S, Asahina Y*, Okamoto R, et al. Bile acid–FXR signaling facilitates the long-term maintenance of hepatic characteristics in human iPSC-derived organoids. Cell Rep 2025 in press.
5. Tsuchiya J, Miyoshi M, Kakinuma S, Kawai-Kitahata F, Kamiya A, Shimizu T, Sato A, Watakabe K, TMochida T, Inada K, Kamimae R, Kaneko S, MurakawaM, Nitta S, Nakagawa M, Watanabe M, Asahina Y*, Okamoto. HBV-KMT2B integration drives hepatic oncogenic processes in a human gene-edited iPSC-derived model. Cell Mol Gastroenterol Hepatol 2025; 19(2): 101422. doi: 10.1016/j.jcmgh.2024.101422.
6. Watakabe K, Miyoshi M, Kakinuma S, Sato A, Tsuchiya J, Shimizu T, Mochida T, Inada K, Kaneko S, Kawai-Kitahata F, Murakawa M, Nitta S, Nakagawa M, Oshima S, Watanabe M, Ma A, Asahina Y*, Okamoto R. A20 in hepatic stellate cells suppresses chronic hepatitis by inhibiting DCLK1-JNK pathway-dependent chemokines. FASEB Journal 2024 Jul 15; 38(13): e23757. doi: 10.1096/fj.202400109R.
7. Kaneko S, Asahina Y, Murakawa M, Ueyama S, Maeyashiki C, Watanabe H, Kusano-Kitazume A, Sato A, Uchidate K, Asakawa T, Watanabe S, Iizuka Y, Shibata I, Oooka S, Karakama Y, Fujii T, Watabe T, Akahoshi K, Tanabe M, Inada K, Mochida T, Watakabe K, Shimizu T, Tsuchiya J, Miyoshi M, Kitahata-Kawai F, Nitta S, Nakagawa M, Kakinuma S, Okamoto R. Prognostic Significance of C-Reactive Protein in Unresectable Hepatocellular Carcinoma treated with Atezolizumab and Bevacizumab. Hepatol Res 2024 Jun;54(6):562-574. doi: 10.1111/hepr.14001.
8. Suzuki Y, Maekawa S, Osawa L, Komiyama Y, Takada H, Muraoka M, Sato M, Takano S, Morisaka H, Onishi H, Enomoto N. 2025. Evaluation of weight loss and improvement of steatotic liver disease using magnetic resonance imaging in patients with metabolic dysfunction associated steatotic liver disease. Hepatology Research.
9. Nakakuki N, Maekawa S, Takano S, Osawa L, Komiyama Y, Takada H, Muraoka M, Suzuki Y, Sato M, Enomoto N. 2025. TCR Repertoire Analysis During Therapeutic Interventions in Liver Diseases Using Next-Generation Sequencing. J Gastroenterol Hepatol 40:537-547.
10. Yamauchi K, Maekawa S, Osawa L, Komiyama Y, Nakakuki N, Takada H, Muraoka M, Suzuki Y, Sato M, Takano S, Enomoto N. 2024. Single-molecule sequencing of the whole HCV genome revealed envelope deletions in decompensated cirrhosis associated with NS2 and NS5A mutations. J Gastroenterol 59:1021-1036.